Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pegozafermin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Participants will receive pegozafermin as per the schedule specified in the protocol in the abdomen. |
| Group B | EXPERIMENTAL | Participants will receive pegozafermin as per the schedule specified in the protocol in the thigh. |
| Group C | EXPERIMENTAL | Participants will receive pegozafermin as per the schedule specified in the protocol in the upper arm. |
| Name | Type | Description |
|---|---|---|
| Pegozafermin | DRUG | Pergozafermin will be administered as specified in the protocol. |
Inclusion Criteria: * Participants with a body mass index (BMI) within the range of 18.5-35.0 kilogram per square meter (kg/m²) * Participants in good health, as determined by medical history, physical examination findings, vital signs, electrocardiogram (ECG), and clinical laboratory tests at scre...
Pegozafermin is an investigational small molecule being developed by Roche Holding AG (ticker RHHBY). It is currently in Phase 1 clinical development. The specific disease indications for pegozafermin have not been disclosed, and the program is categorized under a therapeutic area outside the main disease categories tracked.
Pegozafermin is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating pegozafermin. The drug is an investigational small molecule and remains in Phase 1 development.
Pegozafermin is in Phase 1 clinical development. It is an investigational small molecule and has not been approved for any indication. One Phase 1 trial is registered, and it is currently listed as not yet recruiting.
Pegozafermin is being studied in one registered Phase 1 trial, NCT07835243, titled a study to assess the effect of subcutaneous injection site on the pharmacokinetics of pegozafermin in healthy participants. The trial is controlled, randomized, and plans to enroll 105 healthy volunteers aged 18 years and older. It is not yet recruiting.
Pegozafermin is not approved. It is an investigational small molecule in Phase 1 clinical development, and its only registered trial is a pharmacokinetic study in healthy volunteers. No approval status has been granted for any indication.